David Fuentes, MD
Allergy · Boerne, TXNPI 1013911544
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,374 of the $13,366 with a category attached, or 70.1%. It is spread thinly across 41 manufacturers, the largest accounting for just 15.6%. Reporting peaked in 2019 at $3,788 and has fallen 50.9% since, to $1,859 in 2025.
Across 355 payments — averaging $37.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Chiesi USA, Inc.$2K
- Astrazeneca UK Limited$2K
- Sanofi-aventis U.S. LLC$915
- GSK$869
- Alk-abello, Inc$770
- plus $5K from 35 others
Across 1,695 payments — averaging $8529.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$4M
- AstraZeneca$3.1M
- Genentech, Inc.$2.3M
- GSK$1.5M
- Novartis$873K
- Chiesi USA, Inc.$610K
- plus $2M from 10 others
What the payments were for
- Consulting fees$240%
- Travel & lodging$3,82529%
- Food & beverage$9,37470%
- Education$1441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,366 in reported general payments places this provider in the 85th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $149,341 |
| Dupixent SyringeDupilumab | 18 | $79,639 |
| Dupixent PenDupilumab | 13 | $44,616 |
| Breo ElliptaFluticasone/Vilanterol | 72 | $30,774 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $20,466 |
| XhanceFluticasone Propionate | 12 | $13,909 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $6,695 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,158 |
| Pulmicort FlexhalerBudesonide | 14 | $5,619 |
| RyaltrisOlopatadine Hcl/Mometasone | 17 | $4,931 |
| Ipratropium Bromide | 177 | $4,826 |
| DuleraMometasone/Formoterol | 13 | $4,629 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 28 | $3,969 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,313 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $869 | $186,273258 claims |
| AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort | $2,088 | $29,39756 claims |
| Optinose US, Inc.Xhance | $205 | $13,90912 claims |
| Hikma Pharmaceuticals USARyaltris | $80 | $4,93117 claims |
| MerckDulera | $35 | $4,62913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 69 allergy providers in Texas.
Other allergy in Boerne
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
- Patricia DingerSan Antonio$15K
- Brian MillerGeorgetown$15K
- Carlos VitalHouston$14K
- David EnglerHouston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.